10.8× Alzheimer's Risk. No Symptoms. No Warning.
A 45-year-old with no family history and no symptoms underwent a DxMapper polygenic risk screen — and discovered a genomic risk profile that changed his life's trajectory, years before it would have mattered too late.
Important: DxMapper's polygenic risk scores identify elevated genomic predisposition — they are not clinical diagnoses. A high risk score means an individual carries more genomic variants associated with a condition than average. It does not predict with certainty that the condition will develop. All findings are shared in the context of a clinical consultation designed to support informed, proactive decision-making.
The Findings
What a Standard Checkup Would Never Find
10.8×
Odds ratio for late-onset Alzheimer's
Relative to the general population baseline
ε4/ε4
APOE genotype confirmed
Present in fewer than 3% of the general population
0
Symptoms at time of testing
Asymptomatic, active, no family history
Why APOE ε4/ε4 Matters
The APOE gene has three common variants: ε2, ε3, and ε4. Inheriting one copy of ε4 elevates Alzheimer's risk meaningfully. Inheriting two copies — one from each parent — represents the highest known common genomic risk factor for late-onset Alzheimer's disease.
Most carriers of this genotype have no idea. There is no standard clinical test that screens for it. No family history would necessarily predict it. Without a proactive genomic screen, this patient would have continued on his current path — unaware — until symptoms emerged, at which point the window for meaningful intervention narrows substantially.
How It Unfolded
The DxMapper Journey
Routine DxMapper Screen
A 45-year-old male enrolled in his employer's DxMapper benefit. He was asymptomatic, active, and had no family history of Alzheimer's disease. He underwent a full polygenic risk score (PRS) panel across DxMapper's covered conditions.
PRS Reveals Elevated Alzheimer's Risk
His polygenic risk score for late-onset Alzheimer's disease returned an odds ratio of 10.8× relative to the general population. This means he carried a significantly higher burden of Alzheimer's-associated genomic variants than 99% of individuals — something no physical exam, family history, or standard screening would have revealed.
Targeted APOE Sequencing
Following clinical protocol, targeted sequencing of the APOE gene was performed. Results confirmed he was an APOE ε4/ε4 carrier — the highest-risk genotype for late-onset Alzheimer's disease, present in fewer than 3% of the general population. The PRS and APOE findings were consistent and mutually reinforcing.
Clinical Consultation & Informed Planning
The patient is offered a consultation with a medical professional to review the findings, their significance, and their limitations — including what the results mean, and critically, what they do not mean. The goal is clarity, context, and a proactive path forward.
The Value of Early Knowledge
What Years of Lead Time Make Possible
Alzheimer's research has accelerated dramatically. Disease-modifying therapies are emerging. Clinical trials are enrolling. None of this is accessible without knowing your risk. Years of advance notice isn't just peace of mind — it's time that can be used.
Lifestyle Optimization
Aerobic exercise, sleep hygiene, and dietary interventions have demonstrated measurable effects on Alzheimer's risk reduction in APOE4 carriers. With years of lead time, he began implementing evidence-based lifestyle changes with his physician — modifications that are most effective when started early.
Clinical Trial Eligibility
APOE ε4/ε4 carriers are actively recruited for clinical trials investigating Alzheimer's prevention and early intervention. With his genomic status confirmed and documented, he was able to explore enrollment in programs that are specifically designed for individuals at his risk level — access that simply isn't available without this knowledge.
Financial & Family Planning
Alzheimer's disease has significant financial and caregiving implications. With years of advance notice, he was able to make informed decisions about long-term care insurance, estate planning, and open conversations with his family — removing the uncertainty and urgency that comes with a late or emergency diagnosis.
Ongoing Medical Monitoring
His care team now has context that will inform future clinical decisions — from medication selection to cognitive screening protocols. Certain medications are known to carry higher risks for APOE4 carriers. This genomic knowledge becomes a permanent, clinically actionable part of his medical record.
The Bigger Picture
76% of Members with Hidden Risk Have No Idea
Across DxMapper's covered conditions — including cardiovascular disease, hereditary cancers, diabetes, and neurodegenerative disorders — the vast majority of individuals with elevated genomic risk have no clinical warning signs. No family history. No symptoms. Nothing a standard annual physical would catch.
DxMapper finds what routine medicine misses — and gives individuals and their care teams the time and information to act.
Add DxMapper to Your Benefit
How Many of Your Members Are Carrying Risk They Don't Know About?
A single DNA test, included in your MapperHealth benefit, screens for elevated genomic risk across 12 serious conditions — including Alzheimer's, hereditary cancers, and cardiovascular disease.